Down large today. They announced earnings after the bell tomorrow. AH trading not looking good for this company. Larry and Plaus dogged this board for a year, because they were long PHRM. What goes around comes around. Think it's important to hear numbers on Vidaza and any hint as to how it's holding up against the competition. I would be surprised if Vidaza sales didn't slip some to give Dacogen such great growth in the second quarter.
Go to nasdaq.com 15 min delay - not very many shares yet.
AH on PHRM, this looks like neutral news. Still think it's important to listen to any developments. Got to take your hat off to MGI sales staff. They did a great job on increasing sales. They did it without just stealing business. Organic growth is the best. On the Dacogen front...PHRM stated they will have news on survival in 3-6 weeks. So they are ahead of the curve on AML.
Do you know offhand any of the survival tests going on? My perception is that both drugs are following the patients from the phase 3 study and compiling the info from that.
I few months ago. I read much about the efficacy of both drugs. The efficacy of dacogen was probably 5-10% better based on the partial and complete response rates. Hence, Dr Piros of R&R has commented frequently about the non-inferiority of Dacogen. The side effects of both was similar as I recall.
Do you think this slightly better efficacy is causing the quick acceptance of dacogen?
Sales were 32.5M up from 31.3M on Vidaza.
They also increased the EU sales to 8m from 6.4m.
We could see next quarter about 3M in outside U.S. sales and a extra $675,000 per quarter sales increase. This would add a penny to EPS. I got my estimate from what vidaza started off outside U.S. and I believe JNJ is larger and has better connections.
BOULDER, Colo., July 25 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM - News) today reported financial results for its quarter ended June 30, 2007. Second quarter net sales totaled $65.8 million, compared to $60.4 million in the second quarter of 2006. Worldwide sales of Vidaza� (azacitidine for injection) totaled $40.5 million in the second quarter of 2007, compared to $36.1 million in the same quarter of 2006. In the U.S., sales of Vidaza totaled $32.5 million in the second quarter of 2007, compared to $33.7 million in the same quarter of 2006, reflecting relatively constant sales despite the entry of two competitive products to the U.S. Myelodysplastic Syndromes (MDS) market during 2006. Named patient and compassionate use sales of Vidaza in Europe and other international markets totaled $8.0 million in the second quarter of 2007, compared to $2.4 million in the second quarter of 2006. Sales of Thalidomide, including named patient and compassionate use sales in Europe, totaled $20.4 million in the second quarter of 2007, compared to $19.1 million in the same period of 2006.
Last quarter PHRM had sales of Vidaza
In U.S. 31.3M
Compassionate EU 6.4M
I expect we may see them dip under 30M in the U.S on this report. Company will have to address this issue in some depth.
The AH fall on PHRM was because of a FDA request for more info on another drug that PHRM wants to distribute in EU. I will want to hear what they have to say about Vidaza sales. Something had to give for Dacogen to do so well.